Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in Spain / NCT07310693
Recruiting Observational

External Validation of the CLOVER Score for Detecting Occult Cancer in Venous Thromboembolism Patients

NCT07310693 · tracked via the Priya Life Science Spain tracker
Sponsor
Infanta Leonor University Hospital
Phase
Observational
Started
2025-12-01
Last updated
2025-12-30

Condition(s) studied

Venous Thromboembolism (VTE)Occult Cancer

Study summary

This study aims to externally validate the CLOVER score, a machine learning-based predictive model designed to identify patients with venous thromboembolism (VTE) who are at increased risk of having an occult cancer. The study includes a retrospective cohort of patients with acute symptomatic VTE diagnosed between 2000 and 2022, and a prospective cohort of consecutively recruited patients from December 2025 to December 2027. The CLOVER model will be applied to all participants, and its ability to discriminate between patients with and without occult cancer will be evaluated. The study also assesses clinicians' satisfaction with the web-based tool (CLOVER-Web) developed to facilitate the use of the score in clinical practice.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Age ≥18 years. * Objectively confirmed acute symptomatic venous thromboembolism (deep vein thrombosis and/or pulmonary embolism). * Ability to provide written or electronic informed consent. Exclusion Criteria: * Suspicion of cancer during the initial diagnostic evaluation for VTE. * Participation in another interventional study that may interfere with outcomes. * Inability or refusal to provide informed consent.

Primary outcome measure(s)

Trial sites (12)

FacilityCityRegionStatus
Hospital Clínic Barcelona Barcelona Recruiting
Hospital Universitario Infanta Leonor Madrid Madrid Recruiting
Hospital Universitario La Paz Madrid Madrid Recruiting
Hospital Universitario Príncipe de Asturias Madrid Madrid Recruiting
Hospital Universitatio del Sureste Madrid Madrid Recruiting
Hospital Universitario de Móstoles Madrid Madrid Recruiting
Hospital Clínico Universitario Virgen de la Arrixaca Murcia Murcia Recruiting
Hospital Universitario Morales Meseguer Murcia Murcia Recruiting
Hospital San Agustín Avilés Principality of Asturias Recruiting
Hospital Universitario Son Llatzer Balea Spain Recruiting
Hospital Universitario 12 de Octubre Madrid Spain Recruiting
Hospital Universitario de Fuenlabrada Madrid Spain Recruiting

More Infanta Leonor University Hospital trials in Spain

AI-THEROSCOPE: AI Detection of Subclinical Atherosclerosis From Retinal Images Active, not recruiting
Infectious Complications in Hematological Patients Under Treatment With Bispecific Antibodies. Recruiting
Observational Study to Evaluate the Effectiveness of DOACS for Secondary Thrombosis Prevention in Low-risk Thrombotic APS Patients Recruiting
Identification of Patients With Advanced Chronic Diseases in Need of Palliative Care Active, not recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07310693 on ClinicalTrials.gov ↗ ← All trials in Spain